Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H24N2O3S |
| Molecular Weight | 372.481 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)[C@@H]2SC3=C(C=CC=C3)N(CCN(C)C)C(=O)[C@@H]2O
InChI
InChIKey=NZHUXMZTSSZXSB-MOPGFXCFSA-N
InChI=1S/C20H24N2O3S/c1-21(2)12-13-22-16-6-4-5-7-17(16)26-19(18(23)20(22)24)14-8-10-15(25-3)11-9-14/h4-11,18-19,23H,12-13H2,1-3H3/t18-,19+/m1/s1
| Molecular Formula | C20H24N2O3S |
| Molecular Weight | 372.481 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The role of calcium antagonists in chronic kidney disease. | 2004-03 |
|
| Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. | 2002-10 |
|
| Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. | 2002 |
|
| Slowing the progression of renal disease in diabetic patients. | 2001-04 |
|
| Effects of diltiazem on down-regulation of lymphocyte beta-adrenoceptors in patients with chronic congestive heart failure. | 2000-10 |
|
| An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. | 2000-09 |
|
| The effect of calcium channel blockers on cerebral oxygenation during tracheal extubation. | 2000-08 |
|
| Effects of diltiazem retard on ambulatory blood pressure and heart rate variability in patients with essential hypertension. | 2000-06 |
|
| The interaction of diltiazem with simvastatin. | 2000-03 |
|
| Increased urinary cortisol and androgen metabolites in a young female with hypertension: partial glucocorticoid resistance syndrome. | 2000 |
|
| Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. | 1999-04 |
|
| Probable diltiazem-induced acute interstitial nephritis. | 1998-06 |
|
| Lower incidence of liver graft rejection in patients on diltiazem plus cyclosporine therapy. | 1998-06 |
|
| Relative bioavailability of Cardizem CD and Tiazac controlled-release diltiazem dosage forms after single and multiple dosing in healthy volunteers. | 1998-05 |
|
| [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients]. | 1997-10-15 |
|
| Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. | 1996-05-28 |
|
| Inhibitory effects of TA-993, a new 1,5-benzothiazepine derivative, on platelet aggregation. | 1996-04 |
|
| Anaphylatoxin C3a induces rapid protein phosphorylation in guinea pig platelets. | 1994-09-01 |
|
| Effect of diltiazem and low-dose aspirin on platelet aggregation and ATP release induced by paired agonists. | 1993-08-02 |
|
| The influence of diltiazem versus cimetidine on propranolol metabolism. | 1992-12 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:24:01 GMT 2025
by
admin
on
Mon Mar 31 18:24:01 GMT 2025
|
| Record UNII |
849UT193YJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
91638
Created by
admin on Mon Mar 31 18:24:01 GMT 2025 , Edited by admin on Mon Mar 31 18:24:01 GMT 2025
|
PRIMARY | |||
|
SUB112491
Created by
admin on Mon Mar 31 18:24:01 GMT 2025 , Edited by admin on Mon Mar 31 18:24:01 GMT 2025
|
PRIMARY | |||
|
C037769
Created by
admin on Mon Mar 31 18:24:01 GMT 2025 , Edited by admin on Mon Mar 31 18:24:01 GMT 2025
|
PRIMARY | |||
|
91602-22-1
Created by
admin on Mon Mar 31 18:24:01 GMT 2025 , Edited by admin on Mon Mar 31 18:24:01 GMT 2025
|
SUPERSEDED | |||
|
100000142066
Created by
admin on Mon Mar 31 18:24:01 GMT 2025 , Edited by admin on Mon Mar 31 18:24:01 GMT 2025
|
PRIMARY | |||
|
42399-40-6
Created by
admin on Mon Mar 31 18:24:01 GMT 2025 , Edited by admin on Mon Mar 31 18:24:01 GMT 2025
|
PRIMARY | |||
|
255-795-9
Created by
admin on Mon Mar 31 18:24:01 GMT 2025 , Edited by admin on Mon Mar 31 18:24:01 GMT 2025
|
PRIMARY | |||
|
DTXSID00881093
Created by
admin on Mon Mar 31 18:24:01 GMT 2025 , Edited by admin on Mon Mar 31 18:24:01 GMT 2025
|
PRIMARY | |||
|
849UT193YJ
Created by
admin on Mon Mar 31 18:24:01 GMT 2025 , Edited by admin on Mon Mar 31 18:24:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BINDER->LIGAND |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|